



**HAL**  
open science

# Hospitalization and Death in the First 30 days After Outpatient Lower Extremity Arterial Stenting

Simon Jan, Yann Gouëffic, Olivier Grimaud, Nolwenn Le Meur

► **To cite this version:**

Simon Jan, Yann Gouëffic, Olivier Grimaud, Nolwenn Le Meur. Hospitalization and Death in the First 30 days After Outpatient Lower Extremity Arterial Stenting. CardioVascular and Interventional Radiology, 2022, 45, pp.1441-1450. 10.1007/s00270-022-03193-0 . hal-03704186

**HAL Id: hal-03704186**

**<https://ehesp.hal.science/hal-03704186>**

Submitted on 15 Sep 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Original article**

2 **Hospitalization and death in the first 30 days after outpatient lower extremity arterial**  
3 **stenting**

4 Simon Jan, MD ; Yann Gouëffic, MD, PhD ; Olivier Grimaud, MD, PhD ; and Nolwenn Le  
5 Meur, PhD

6

7 **Short title:** Early adverse events after outpatient lower limb stenting

8

9 **Affiliations and addresses**

10 Simon Jan, MD

11 Observatoire Régional de la Santé, Bretagne, France

12 Address: Immeuble Acropole

13 19 Avenue Charles Tillon

14 35 000 Rennes - FR

15

16 Yann Gouëffic, MD, PhD

17 Groupe hospitalier Paris St Joseph, Service de chirurgie vasculaire et endovasculaire, F-75014.

18 Address: Hôpital Paris St Joseph, Vascular and endovascular surgical center

19 75014 Paris – FR

20

21 Olivier Grimaud, MD, PhD

22 *Univ Rennes, EHESP, CNRS, Inserm, Arènes - UMR 6051, RSMS - U 1309 – F-35000*

23 *Rennes, France*

24 Address : Écoles des Hautes Études en Santé Publique

25 Département METIS,

26 15 Avenue du Professeur Léon Bernard, CS 74312 35043 Rennes Cedex, FR

27

28 **Corresponding author:**

29 Nolwenn Le Meur, PhD

30 *Univ Rennes, EHESP, CNRS, Inserm, Arènes - UMR 6051, RSMS - U 1309 – F-35000*

31 *Rennes, France*

32 Address : Écoles des Hautes Études en Santé Publique

33 Département METIS,

34 15 Avenue du Professeur Léon Bernard, CS 74312 35043 Rennes Cedex, FR

35 e-mail: nolwenn.lemeur@ehesp.fr

36 Phone: +33 2 99 02 25 14

37

1 **Abstract**

2 **Purpose** To compare the safety of outpatient versus inpatient endovascular treatment of lower  
3 extremity arterial disease (LEAD) using real-life data.

4 **Materials and Methods**

5 This retrospective observational study used real-life data from the French national health data  
6 information system on adult patients who underwent stenting for LEAD between 2013 and  
7 2016. The outcomes of interest were all-cause mortality, all-cause hospitalization, planned  
8 hospitalization, and unplanned hospitalization at day 3 and day 30 after the index endovascular  
9 intervention for LEAD revascularization. A propensity score was used to control for indication  
10 bias. Outcome rates in outpatient and inpatient settings were compared with the Poisson  
11 regression model. Sensitivity analyses were performed by varying the definition of the  
12 outcomes of interest.

13 **Results** During the study period, 26 715 interventions were performed among which 2 819  
14 (10.6%) were in outpatient settings. Outpatients were slightly younger than inpatients (64.73  
15  $\pm 10.68$  versus 68.10  $\pm 11.50$ , respectively). The percentage of women patients was similar:  
16 19.8% in the outpatient group and 27.2% in the inpatient group. Within 30 days after discharge,  
17 73 patients (.31%) and 2 (.07%) patients ( $p = .02$ ) died in the inpatient group and outpatient  
18 group, respectively. The death and rehospitalization rate were similar: 3.8 and 3.5 per 1 000  
19 person-months for inpatients and outpatients, respectively. No difference was observed after  
20 adjusting for patients' case-mix in the regression model (RR = .99; 95% CI [.82-1.19]).

21 **Conclusions** Outpatient stenting for LEAD did not present any additional risk of early  
22 postoperative rehospitalization or death compared with inpatient stenting.

23

24 **Keywords** lower extremity arterial disease; endovascular intervention; complication;  
25 outpatient; death; rehospitalization

26

## 1 **Introduction**

2 Lower extremity arterial disease (LEAD) is the third cause of cardiovascular morbidity after  
3 coronary artery disease and stroke. LEAD prevalence in  $\geq 70$  adults is estimated at 15-20%  
4 [1,2]. Inpatient invasive surgical bypass procedures have been the main treatment for LEAD  
5 [3]; however, recent technical progress in minimally invasive surgery, particularly in  
6 endovascular revascularization, has contributed to reduce the constraints and risks associated  
7 with open surgery (e.g. general anesthesia, long hospital stay, surgical site or hospital  
8 acquired infections)[4,5]. Accordingly, the guidelines for vascular and endovascular surgical  
9 treatments promote endovascular revascularization instead of open surgery for LEAD [6,7].  
10 Moreover, several studies demonstrated the feasibility of same-day endovascular  
11 revascularization (*i.e.* outpatient surgery) [8–11] and the reduced risk of hospital-acquired  
12 infections [12]. Consequently, outpatient endovascular revascularization has become the main  
13 option for arterial repair in the United States of America (USA) where the Outpatient  
14 Prospective Payment System significantly promotes the shift from inpatient to outpatient  
15 settings [13]. However, outpatient setting for LEAD remains low elsewhere[14], notably in  
16 France where the proportion of outpatients average 5% and stable since 2016.  
17 Some studies showed that procedural and postoperative complications of endovascular  
18 revascularization within 30 days of surgery occur in 10% to 13% of the patients [15,16]. In  
19 addition, outpatient endovascular repair for LEAD does not seem to increase the risk of  
20 complications and hospital readmission [8,16–18]; however, the AMBUVASC randomized  
21 clinical trial (RCT) showed more readmissions in the outpatient than in the inpatient arm [19].  
22 As real-life patients differ from those enrolled in RCT, the evidence from the AMBUVASC  
23 RCT may be insufficient to draw firm conclusions on the risk of readmission after outpatient  
24 endovascular revascularization. Therefore, we analyzed real-life hospital discharge data to

1 determine the early readmission and death rates after inpatient and outpatient endovascular  
2 treatment of LEAD.

### 3 **Materials and Methods**

#### 4 *Data sources*

5 This retrospective observational study was performed using real-life healthcare data extracted  
6 from the French national health data system (SNDS). SNDS contains anonymous individual  
7 sociodemographic and medical information on >98% of the French population [20]. The  
8 medical data include all reimbursed healthcare procedures, such as ambulatory consultations,  
9 prescribed drugs, and outpatient and inpatient surgeries.

#### 10 *Study population*

11 All adult patients who underwent at least one stenting intervention for LEAD between March  
12 1, 2013, and June 30, 2016, were included (Fig. 1). The study period started in March to  
13 integrate the yearly update of the medical nomenclature coding. The clinical selection criteria  
14 were based on twelve surgical procedures identified by the *French Classification of Medical*  
15 *Procedures (CCAM)* and the six main hospital discharge diagnoses identified by the  
16 *International Classification of Diseases, 10th Revision (ICD10)* (Supplementary Table 1).  
17 The surgery setting, defined on the basis of the hospital stay duration in the hospital discharge  
18 summary, was used to categorize patients into: inpatients (at least one overnight stay) and  
19 outpatients (same-day discharge)[21]. To compare homogeneous groups of patients,  
20 inpatients with features that would have precluded outpatient surgery were excluded (Fig. 1).  
21 For each patient, the comorbidity level was computed using hospital discharge data from up  
22 to 1 year before the index intervention and the Charlson's comorbidity index coding  
23 algorithm [22,23] . Other covariates were the age, the sex, the year of the index surgery, and

1 the hospital activity, defined by the number of LEAD revascularization procedures performed  
2 in that hospital between 2013 and 2016.

### 3 ***Outcomes***

4 The outcomes of interest were all-cause mortality, all-cause hospitalization, planned  
5 hospitalization, and unplanned hospitalization at day 3 and day 30 after the index  
6 endovascular revascularization for LEAD. All-cause hospitalization included any  
7 hospitalization with at least one overnight stay, or admission through the emergency  
8 department, or another treatment for LEAD in outpatient setting. Unplanned hospitalizations  
9 were considered as postoperative complications and were divided in three categories by two  
10 of the authors (SJ: medical doctor and YG: vascular surgeon): endovascular procedure-  
11 related, cardiovascular comorbidity-related, and other reasons (Supplementary Table 2).  
12 Planned hospitalizations included all other causes of admissions. The time to event was  
13 calculated as the number of days from the index surgery date to the subsequent hospitalization  
14 date. For patients with several readmissions after the index surgery, only the first one was  
15 counted and analyzed based on the assumption that the earliest admission was probably  
16 related to the index intervention.

### 17 ***Statistical analyses***

18 The patients' characteristics were described for the outpatient and inpatients groups. Age was  
19 presented as mean and standard deviation. Sex, comorbidities, and year of intervention were  
20 described using numbers and percentages. The absolute and relative frequencies of  
21 interventions were reported by hospital activity level to highlight any hospital size effect.  
22 To determine differences between groups, the standardized difference method was used with  
23 the following thresholds for significant differences: low [0.2-0.3[, moderate [0.3-0.8], and high  
24 >0.8. To address a possible indication bias within the two groups, the inverse probability

1 treatment weighting (IPTW) was used[24]. Variables included in the propensity score were sex,  
2 age, comorbidities, year of intervention, and the hospital activity. Adjustments were considered  
3 satisfying when the standardized differences between groups were  $\leq 0.1$ .

4 Outcomes were summarized for the outpatient and inpatients groups. Unplanned  
5 hospitalizations were reported as the cumulative number of events and their relative  
6 proportions at day 3 and day 30 days after the index endovascular revascularization. The daily  
7 occurrence of outcomes over the 30-day period after the index surgery was plotted in function  
8 of the hospitalization type (all-cause, planned, unplanned) and surgery setting.

### 9 ***Regression model and sensitivity analysis***

10 A Poisson regression model with robust estimates of the standard errors was used to compare  
11 the mortality and hospitalization rates between inpatients and outpatients in the 30 days after  
12 the index endovascular revascularization [25]. Although strict selection criteria were used to  
13 obtain comparable outpatient and inpatient groups (Fig. 1), IPTW was applied to address  
14 possible indication bias in the regression analysis [24].

15 A sensitive analysis was performed by changing the definition of the outcomes of interest in  
16 the Poisson regression model to assess the robustness of the comparison between inpatients and  
17 outpatients. The modified definitions were: (i) very early readmission ( $\leq 3$  days); (ii) death or  
18 readmission through the emergency department; (iii) readmission related exclusively to the  
19 procedure; and (iv) readmission related to cardiovascular comorbidities.

20 All p values  $< .05$  were considered statistically significant. Data management and statistical  
21 analyses were performed using the R statistical software (version 3.6.1) [26].

## 22 **Results**

23 During the study period, 133 992 hospital stays for LEAD stenting were identified (Fig. 1).

24 After applying the exclusion criteria, 26 716 hospital stays were considered as potentially

1 eligible for outpatient management. The propensity score could not be calculated for one  
2 patient. In total, 26 715 stays were included in the analysis.

### 3 ***Patients' characteristics***

4 Among the 26 715 interventions, 2 819 (10.6%) were performed in an outpatient setting  
5 (Table 1), and their percentage tended to increase from 2013 to 2016. In the Outpatient group,  
6 patients were younger (mean age:  $64.7 \pm 10.68$  years vs  $68.10 \pm 11.50$  years), less frequently  
7 women (19.8% vs. 27.2%), and had fewer comorbidities. Diabetes, cardiovascular and  
8 chronic obstructive pulmonary diseases were the most frequent comorbidities in both groups  
9 (11.3% and 22.0%, 10% and 18.5%, 5.1% and 9.1% of outpatients and inpatients,  
10 respectively).

### 11 ***Mortality and hospitalization rates within 30 days***

12 Within 30 days after discharge, 73 (0.31%) and 2 (0.07%) patients died among the inpatients  
13 and outpatients, respectively ( $p = .02$ ) (Table 2). Twenty-six patients died at home without  
14 any post-surgery hospitalization; 33 died during their first readmission, and 16 after repeated  
15 hospitalizations. The deceased patients were significantly older (mean age  $77 \pm 13$  years), more  
16 often men, and had more comorbidities.

17 Within 30 days after discharge, 2 799 patients ( $n = 281$  outpatients, 9.9%, and  $n = 2 518$   
18 inpatients, 10.4%;  $p = .35$ ) were readmitted to hospital. Hospitalizations followed a weekly  
19 temporal trend (Fig. 2). The first peak of hospitalizations was observed within 5 and 6 days,  
20 and then every 7 days. Approximately 50% of all recorded readmissions were within the first  
21 14 days after discharge. Part of this phenomenon could be explained by the weekend bias in  
22 hospital discharge reporting. However, it also represented scheduled consultations for post-  
23 operative surveillance or programmed endovascular revascularization of the other limb. Most  
24 of these hospitalizations were for LEAD endovascular procedures ( $n = 1 075$ ; 66.9%),



1 revascularization by open surgery for LEAD (n = 443; 27.6%), or other revascularization  
2 interventions (n = 89; 5.5%). These 1 607 (55.9%) hospitalizations were qualified as  
3 “planned”. The remaining 1 267 (44.1%) hospitalizations were qualified as “unplanned” and  
4 related to postoperative complications.

5 Postoperative complications within 30 days after surgery were reported for 1 267 patients  
6 with a significant higher percentage in the inpatient than outpatient group (4.9% vs 3.72%, p  
7 < 1.10<sup>-5</sup>). In the inpatient group, the peak of unplanned hospitalizations occurred 5 days after  
8 discharge, and about two third of these hospitalizations were within the first 15 days. In the  
9 outpatient group, most unplanned hospitalizations occurred within the first 14 days (Fig. 3).

10 Complications were related to the endovascular procedure (23.4% of cases), cardiovascular  
11 comorbidities (26%), and other causes (48.3%) (Supplementary Fig. 1). Among the  
12 endovascular procedure-related complications, false aneurysm was the most frequent in the  
13 outpatient group (22.7% versus 17.2% in the inpatient group), followed by ulcers and  
14 gangrene without amputation (18.1% vs 16.4%). Amputations were a more frequent cause of  
15 hospitalization in the inpatient group (16.4% vs 4.5% in the outpatient group), suggesting that  
16 some patients with severe ischemia were retained in both groups despite our exclusion  
17 criteria. Cardiovascular comorbidity-related complications included heart diseases (46%),  
18 stroke (1%), and other cardiovascular diseases (43%). These events occurred at similar rates  
19 in both groups. Myocardial infarction and stroke represented 11 and 12 complications per 1  
20 000 endovascular procedures, respectively. Endovascular procedure-related complications  
21 occurred more often in the first week after discharge, whereas cardiovascular comorbidity-  
22 related complications were spread over time.

### 23 ***Early death or readmission***

1 In total, 18 (0.7%) patients died within 3 days after discharge, all of them in the inpatient  
2 group (Table 2). The hospitalization rates within 3 days were comparable between inpatients  
3 (n = 266; 1.1%) and outpatients (n=22; 0.78%)(p = .45). Among these early readmissions,  
4 38% were classified as complementary revascularization procedures (38 angioplasties and 37  
5 revascularization surgeries) and possibly planned interventions. Compared with the 30-day  
6 hospitalizations, early readmissions for complications were more frequently related to the  
7 endovascular procedure than to cardiovascular comorbidities (23% and 19%, respectively).

#### 8 *Effect of outcome definition changes*

9 The rates of all-cause hospitalization within 30 days were not significantly different between  
10 outpatients and inpatients (p = .88) (Table 3). Results did not change when other causes of  
11 hospitalization (e.g., cancer, trauma) were excluded (p = .77), or when only procedure-related  
12 complications (p = .52) or comorbidities (p= .53) were considered. Similar results were  
13 obtained also for hospitalizations with transfer via the emergency department (p = .06), and  
14 for very early hospitalizations within 3 days after the index surgery (p = .46). Only the  
15 relative risk of death was reduced to 17% among outpatients.

16

## 1 **Discussion**

2 According to our study, rehospitalization after endovascular stenting occurs in more than 1 in  
3 10 patients with LEAD during the perioperative period. However, when using real-life  
4 hospital discharge data, it is difficult to disentangle between readmissions in the framework of  
5 the planned care trajectory and true postsurgical complications. Based on our medical  
6 expertise, early complications related to the endovascular procedure and to cardiovascular  
7 comorbidities were rare (<3%) and were not associated with the setting (inpatient/outpatient  
8 surgery), when adjusting for the patients' case-mix. Unsurprisingly, early readmissions  
9 (within 3 days) were often related to the procedure, whereas late readmissions (within 4 to 30  
10 days) were more associated with cardiovascular comorbidities. The mortality rate was  
11 significantly lower in the outpatient group, although we cannot exclude that this might be  
12 explained by the remaining differences observed after adjustment for the patient baseline  
13 characteristics.

14  
15 Comparison of our results with other studies is difficult because different health care systems  
16 have different outpatient surgery definitions and organization. For instance, in the USA, the  
17 type of care (outpatient/inpatient) depends mainly on the facility[27]. Outpatient care is often  
18 provided in independent ambulatory surgery centers or in office-based surgeries. In France,  
19 outpatient surgery units remain under the administrative control of hospitals and no financial  
20 incentive was given before 2019 to promote outpatient endovascular surgery. Nevertheless,  
21 we excluded high-risk patients using medical criteria similar to those of other  
22 studies[8,11,19,27] (i.e. the American Society of Anesthesiology score and recent guidelines  
23 [28]). Moreover, the number of patients with diabetes was lower than in most previous studies  
24 (11% and 22% of patients in the outpatient and groups compared with 25% to 33% of  
25 patients[8]). This difference might be the result of overall differences in population health or

1 might be linked to our stringent criteria to obtain comparable inpatient and outpatient groups  
2 (exclusion of patients with arterial wounds and of patients with intercurrent conditions, such  
3 as stroke, coronary artery disease in the last 3 months or hospitalization in the previous  
4 month). For example, we excluded patients with pain at rest. Nevertheless, our rate of  
5 postoperative hospitalizations for complications within 30 days was relatively similar to that  
6 of previous studies [11,17]. In our study, the percentage of post-operative deaths and  
7 complications was 2.5%, whatever the surgery setting, and 1.8% for outpatients only.  
8 Spiliopoulos *et al.* reported rates of 1.4% for major complications and 2.7% for minor  
9 complications (without need of treatment or consequences) in their multi-center study on the  
10 safety and feasibility of day-case endovascular procedures for the management of peripheral  
11 arterial diseases [11]. Lin *et al.* followed 1568 outpatients who underwent office-based  
12 endovascular arterial interventions, and found a postoperative complication rate of 1.5% [17].  
13 Overall, these findings are consistent. although our population coverage may slightly differ  
14 because we focused on patients with LEAD, while other studies included patients with  
15 broader profiles of peripheral arterial diseases. Using Medicare data (a design closer to that of  
16 our study), Turley *et al.* found higher all-cause hospitalization rates at 30 days but their  
17 patients were significantly older and with more comorbidities [27]. Similarly, Ali *et al.* found  
18 higher rates of unplanned readmissions, but their study population had a more complex  
19 clinical background (diabetes, critical limb ischemia with tissue loss)[16]. In our study, the  
20 mortality rate at 30 days was .07% among outpatients, which is significantly lower than the  
21 rate in the studies by Lin *et al.* and Turley *et al.* (0.9%, and 0.18%, respectively) [17,27].  
22 Again, this could be partly explained by the younger mean age of our patients.  
23  
24 The main strength of this study is its nation-wide coverage based on data from the French  
25 national healthcare information system. This data source has been previously used for many

1 epidemiological and public health studies [20]. The second strength is the longitudinal  
2 dimension over a 3-year period allowing the recording of the rare events that are  
3 complications after endovascular surgery. Third, the propensity score weighting based on the  
4 patient's comorbidity helped matching the two groups in the context of a real-life dataset.  
5 Finally, this study demonstrates the interest of analyzing real-life data to complement the  
6 findings of randomized trials, such as AMBUVASC, on the safety of outpatient surgery.  
7  
8 The study is limited by the lack of clinical details on the hospital stays. Therefore, we could  
9 not identify the patients initially scheduled for outpatient surgery whose hospital stay was  
10 converted to inpatient surgery (i.e., outpatient who finally stayed one or more nights). This  
11 may have underestimated the number of scheduled outpatients and of very early  
12 complications (within hours). However, to control for this bias, we excluded all patients who  
13 presented postoperative complications before hospital discharge. Moreover, the LEAD  
14 clinical stage was not available in our database (no symptom listed). To minimize this  
15 limitation, we excluded patients with critical limb ischemia and tissue loss because they were  
16 less likely to be offered outpatient surgery. However, with this approach, we may have  
17 underestimated the complications in the inpatient group. In addition, we did not have  
18 information on the surgery approach (laterality, route, artery treated) and this did not allow us  
19 to formally link the initial surgical procedure with the subsequent hospitalization(s). Indeed,  
20 this population presents a high secondary hospitalization rate at 30 days for contralateral  
21 surgery [29], which makes it more difficult to identify the true complications. In our study,  
22 secondary interventions carried out within one month concerned nearly 6% of the patients  
23 who had undergone angioplasty. To control for this limitation, we categorized all  
24 postoperative causes of hospitalization and limited the follow-up period to 30 days because  
25 we think that a 1-year follow-up, as done in the study by Turley *et al.*, might lead to an

1 overestimation of the complication rate [27]. Finally, few socio-demographic data are  
2 available in our database. For instance, social isolation, which is an exclusion criterion for  
3 outpatient care due to the potential risk of postoperative complications, could not be  
4 considered. Socially isolated patients should have been only in the inpatient group, but we  
5 could not identify them and thus we may have overestimated the number of comparable  
6 inpatients.

## 7 **Conclusions**

8 Using real-life data, we found that outpatient endovascular revascularization for LEAD does  
9 not present any additional risk compared with inpatient surgery. Readmissions and deaths at  
10 30 days following LEAD stenting in outpatient settings are rare (<3%), although patients are  
11 older and often have several comorbidities. Moreover, early complications do not seem to be  
12 associated with the surgery setting. The mortality and complication rates after outpatient  
13 endovascular surgery for LEAD should not prevent vascular surgeons to propose it to their  
14 patients, when possible. Nevertheless, more data are needed to confirm its efficiency as  
15 already highlighted by the AMBUVASC RCT.

16

1 **Author contributions**

2 Simon Jan, Yann Gouëffic and Nolwenn Le Meur were involved in the conception and design  
3 of the study. Simon Jan and Nolwenn Le Meur wrote the article with critical revision were by  
4 Yann Gouëffic and Olivier Grimaud. Statistical analysis and interpretation of the data were  
5 performed by Simon Jan and Nolwenn Le Meur. All four authors approved the final version of  
6 the article.

7

8 **Acknowledgements**

9 The authors would like to acknowledge INDS and CNAMTS for support in accessing the  
10 data. We would like to thank Elisabetta Andermarcher for editing and proofreading this  
11 manuscript. We would like to thank Mathilde Lefort for her advises on the statistical methods.  
12

13 **Compliance with Ethical Standards**

14 **Funding:** This work was supported by the French Health Products Agency as part of the  
15 PEPS platform and the TRACKEDAYS project (TRAjectory of Care for Knowledge on  
16 Endovascular DAY Surgery).

17 **Conflict of interest statement:** Y. Gouëffic reports research funding from Bard, General  
18 Electric, Medtronic, WL Gore, personal fees and grants from Abbott, Bard, Biotronik, Boston  
19 Scientific, Medtronic, Penumbra, Terumo, Vygon, WL Gore (medical advisory board,  
20 educational course, speaking). None of these funds was used for the present work. The other  
21 authors declare that they have no competing interests.

22 **Ethical approval:** For this type of study formal consent is not required. This study was  
23 approved by the Institutional Review Board of the SNDS (agreement #201) and the National  
24 Authority Review Board for data protection (CNIL agreement #1968571).

25 **Informed consent:** For this type of study informed consent is not required

26 **Consent for publication:** For this type of study consent for publication is not required.

27


## 1 **References**

- 2 1. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al.  
3 Comparison of global estimates of prevalence and risk factors for peripheral artery disease in  
4 2000 and 2010: a systematic review and analysis. *Lancet*. 2013;382:1329–40.
- 5 2. Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and  
6 national prevalence and risk factors for peripheral artery disease in 2015: an updated  
7 systematic review and analysis. *Lancet Glob Health*. 2019;7:e1020–30.
- 8 3. Antoniou GA, Georgiadis GS, Antoniou SA, Makar RR, Smout JD, Torella F. Bypass  
9 surgery for chronic lower limb ischaemia. *Cochrane Database Syst Rev*. John Wiley & Sons,  
10 Ltd; 2017;4:CD002000–CD002000.
- 11 4. Indes JE, Pfaff MJ, Farrokhyar F, Brown H, Hashim P, Cheung K, et al. Clinical outcomes  
12 of 5358 patients undergoing direct open bypass or endovascular treatment for aortoiliac  
13 occlusive disease: a systematic review and meta-analysis. *J Endovasc Ther*. 2013;20:443–55.
- 14 5. Sullivan TM, Taylor SM, Blackhurst DW, Langan EM, Cull DL, Carsten CG, et al. Has  
15 endovascular surgery reduced the number of open vascular operations performed by an  
16 established surgical practice? *Journal of Vascular Surgery*. 2002;36:514–9.
- 17 6. Halliday A, Bax JJ. The 2017 ESC Guidelines on the Diagnosis and Treatment of  
18 Peripheral Arterial Diseases, in Collaboration With the European Society for Vascular  
19 Surgery (ESVS). *European Journal of Vascular and Endovascular Surgery*. 2018;55:301–2.
- 20 7. Stoner MC, Calligaro KD, Chaer RA, Dietzek AM, Farber A, Guzman RJ, et al. Reporting  
21 standards of the Society for Vascular Surgery for endovascular treatment of chronic lower  
22 extremity peripheral artery disease. *Journal of Vascular Surgery*. 2016;64:e1–21.
- 23 8. Hauguel A, Maurel B, Bague N, Gouaillier-Vulcain F, Costargent A, Chaillou P, et al.  
24 Management of ambulatory (day case) endovascular procedures for peripheral arterial  
25 disease. *J Cardiovasc Surg (Torino)*. 2017;58:293–304.
- 26 9. Payne SP, Stanton A, Travers P, Glenn D, Hanel KC. Outpatient angioplasty: 4-year  
27 experience in one practice. *Ann R Coll Surg Engl*. 1997;79:331–4.
- 28 10. Akopian G, Katz SG. Peripheral angioplasty with same-day discharge in patients with  
29 intermittent claudication. *J Vasc Surg*. 2006;44:115–8.
- 30 11. Spiliopoulos S, Karnabatidis D, Katsanos K, Diamantopoulos A, Ali T, Kitrou P, et al.  
31 Day-Case Treatment of Peripheral Arterial Disease: Results from a Multi-Center European  
32 Study. *Cardiovasc Intervent Radiol*. 2016;39:1684–91.
- 33 12. Daryapeyma A, Hammar U, Wahlgren CM. Incidence of Healthcare Associated Infections  
34 After Lower Extremity Revascularization Using Antibiotic Treatment as a Marker. *European*  
35 *Journal of Vascular and Endovascular Surgery*. 2016;51:690–5.
- 36 13. Jones WS, Mi X, Qualls LG, Vemulapalli S, Peterson ED, Patel MR, et al. Trends in  
37 Settings for Peripheral Vascular Intervention and the Effect of Changes in the Outpatient




- 1 Prospective Payment System. *Journal of the American College of Cardiology*. 2015;65:920–  
2 7.
- 3 14. Nickinson A, Birmipili P, Weale A, Chetter I, Boyle J, Loftus I, et al. What is the current  
4 practice for managing patients with chronic limb-threatening ischaemia in vascular surgery  
5 services? A survey of UK vascular surgeons. *annals*. 2021;rcsann.2021.0075.
- 6 15. Medical Advisory Secretariat. Stenting for peripheral artery disease of the lower  
7 extremities: an evidence-based analysis. *Ont Health Technol Assess Ser*. 2010;10:1–88.
- 8 16. Ali TZ, Lehman EB, Aziz F. Unplanned return to operating room after lower extremity  
9 endovascular intervention is an independent predictor for hospital readmission. *Journal of*  
10 *Vascular Surgery*. 2017;65:1735-1744.e2.
- 11 17. Lin PH, Yang K-H, Kollmeyer KR, Uceda PV, Ferrara CA, Feldtman RW, et al.  
12 Treatment outcomes and lessons learned from 5134 cases of outpatient office-based  
13 endovascular procedures in a vascular surgical practice. *Vascular*. 2017;25:115–22.
- 14 18. Oskui PM, Kloner RA, Burstein S, Zhiroff K, Kartub BR, Economides C, et al. The  
15 Safety and Efficacy of Peripheral Vascular Procedures Performed in the Outpatient Setting.  
16 *The Journal of Invasive Cardiology*. 2015;27:7.
- 17 19. Gouëffic Y, Pin JL, Sabatier J, Alimi Y, Steinmetz E, Magnan P-E, et al. A Cost  
18 Effectiveness Analysis of Outpatient versus Inpatient Hospitalisation for Lower Extremity  
19 Arterial Disease Endovascular Revascularisation in France: A Randomised Controlled Trial.  
20 *European Journal of Vascular and Endovascular Surgery*. Elsevier; 2021;61:447–55.
- 21 20. Tuppin P, Rudant J, Constantinou P, Gastaldi-Ménager C, Rachas A, de Roquefeuil L, et  
22 al. Value of a national administrative database to guide public decisions: From the système  
23 national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système  
24 national des données de santé (SNDS) in France. *Revue d’Épidémiologie et de Santé*  
25 *Publique*. 2017;65:S149–67.
- 26 21. Lemos P, Jarrett P, Philip BK, International Association for Ambulatory Surgery, British  
27 Association of Day Surgery. *Day surgery: development and practice*. Portugal; International  
28 Association for Ambulatory Surgery; London: British Association of Day Surgery; 2006.
- 29 22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying  
30 prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*.  
31 1987;40:373–83.
- 32 23. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, et al. Coding  
33 Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data:  
34 *Medical Care*. 2005;43:1130–9.
- 35 24. Cole SR, Hernan MA. Constructing Inverse Probability Weights for Marginal Structural  
36 Models. *American Journal of Epidemiology*. 2008;168:656–64.
- 37 25. Cameron AC, Trivedi PK. *Microeconometrics using Stata*. Rev. ed. College Station, Tex:  
38 Stata Press; 2010.

- 1 26. R Core Team. R: A Language and Environment for Statistical Computing [Internet].  
2 Vienna, Austria: R Foundation for Statistical Computing; 2020. Available from:  
3 <https://www.R-project.org/>
- 4 27. Turley RS, Mi X, Qualls LG, Vemulapalli S, Peterson ED, Patel MR, et al. The Effect of  
5 Clinical Care Location on Clinical Outcomes After Peripheral Vascular Intervention in  
6 Medicare Beneficiaries. *JACC: Cardiovascular Interventions*. 2017;10:1161–71.
- 7 28. Alimi Y, Hauguel A, Casbas L, Magnan P-E, Pin J-L, Sabatier J, et al. French Guidelines  
8 for the Management of Ambulatory Endovascular Procedures for Lower Extremity Peripheral  
9 Artery Disease. *Annals of Vascular Surgery* [Internet]. 2019 [cited 2019 Jul 17]; Available  
10 from: <http://www.sciencedirect.com/science/article/pii/S0890509619303498>
- 11 29. Rockley M, Kobewka D, Kunkel E, Nagpal S, McIsaac DI, Thavorn K, et al.  
12 Characteristics of high-cost inpatients with peripheral artery disease. *J Vasc Surg*. 2020;  
13  
14




1  
 2 **Fig. 1** Flow diagram for the selection of comparable hospital stays for outpatient and inpatient  
 3 lower limb stenting in patients with LEAD



1

2 **Fig. 2** Daily percentage of all-cause hospitalizations (planned and unplanned readmissions)  
 3 after the index LEAD endovascular stenting in the outpatient and inpatient groups (n=2,874)



1

2 **Fig. 3 :** Daily percentage of unplanned hospitalizations after the index LEAD endovascular  
 3 stenting in the outpatient and inpatient groups (n=655)

4

5

6

7

8

9

10

11

12

13

14

15

16

17

1 *Supplementary Information*

2 **Hospitalization and death in the first 30 days after outpatient lower extremity arterial**  
3 **stenting**

5 **Supplementary Table 1: Medical procedure (CCAM) for inclusion of LEAD patients**

6

| CCAM           | LABEL   |
|----------------|---|
| <b>DGLF001</b> | Aortobisiliac bifurcated stent-graft stent placement by transcutaneous arterial approach  |
| <b>DGLF002</b> | Aorto-uniiliac covered stent, transcutaneous arterial   |
| <b>EDAF003</b> | Intraluminal dilatation of the common iliac artery and / or external iliac artery with stenting, by transcutaneous arterial approach  |
| <b>EDAF006</b> | Intraluminal dilatation of the internal iliac artery with stenting, transcutaneous artery   |
| <b>EDLF004</b> | Stent-graft placement in the common iliac artery and / or the external iliac artery with embolization of the internal iliac artery by transcutaneous arterial delivery  |
| <b>EDLF007</b> | Stent-graft placement in the internal iliac artery or extradigestive branch of the abdominal aorta via the transcutaneous arterial approach   |
| <b>EDPF006</b> | Recanalization of the common iliac artery and / or the external iliac artery with stent graft placement, transcutaneous arterial  |
| <b>EEAF002</b> | Intraluminal dilatation of a lower extremity artery with intraluminal dilatation of the common iliac artery and / or the ipsilateral external iliac artery with stenting, by the transcutaneous arterial approach |
| <b>EEAF004</b> | Intraluminal dilatation of a lower extremity artery with stent grafting by transcutaneous arterial artery   |
| <b>EEAF006</b> | Intraluminal dilatation of several lower extremity artery with stent graftings by transcutaneous arterial artery  |
| <b>EELF002</b> | Stent-graft placement in lower extremity artery via transcutaneous arterial approach  |
| <b>EEPF001</b> | Recanalization of a lower extremity artery with stenting, by transcutaneous arterial approach   |

7

1 **Supplementary Table 2: Medical procedures (CCAM) and associated diagnosis**  
 2 **precluding outpatient surgery for exclusion of LEAD patients.**  
 3

| <b>CCAM – procedure code</b>   | <b>GROUP LABEL</b>  |
|--|---|
| DDAF003, DDAF004, DDAF006, DDAF007, DDAF008, DDAF009, DDPF002  | Dilatation of coronary artery with stenting   |
| DDAF001, DDAF010, DDFF001, DDFF002   | Dilatation of coronary artery without stenting  |
| DDQH009, DDQH010, DDQH011, DDQH012, DDQH013, DDQH014, DDQH015, DDQJ001, DDRH001  | Coronary artery imaging and treatments  |
| DGAF005, DGAF007, DGAF008, DGLF001, DGLF002, DGLF005, DGPF001, DGPF002, DHAF004  | Dilatation of coronary artery, abdominal or arterial bypass toward lower limb                             |
| EBAF001, EBAF010, EBAF011, ECAF001, ECAF002, ECAF003, ECAF004, ECJF001, ECLF003, ECLF004                                     | Dilation of the carotid artery  |
| ECNF001, ECNF002, ECPF002, ECPF003, ECPF005, ECSF002, ECSF004  | Fibrinolysis or thrombectomy of upper limb artery   |
| EDAF001, EDAF005, EDAF007, EDAF008, EDAF009, EDAF010, EDJF002, EDLF004, EDLF006, EDLF007, EDPF002, EDPF003, EDPF005, EDPF006 | Fibrinolysis or thrombectomy of abdominal or aorto-ilio-fémoral path                                      |
| EDAF001, EDAF005, EDAF007, EDAF008, EDAF009, EDAF010, EDJF002, EDLF004, EDLF006, EDLF007, EDPF002, EDPF003, EDPF005, EDPF006 | Dilatation of renal or digestive artery   |
| EDSF004, EDSF005, EDSF009, EDSF010, EDSF012, EDSF013, EDSF014, EDSF016   | Embolization  |
| EEJF001, EELF002, EENF001, EENF002, EESF001, EESF006, EESF007  | Selective or hyper-selective in situ fibrinolysis or embolization of an artery or arterial bypass         |
| EFPF001, EGAF002, EGPF001, ENAF001, ENAF002, ENFF001, ENNF001, EZAF002   | Recanalization of the external iliac vein or Intraluminal dilation of a non-anatomic limb arterial bypass |
| EQLF003, GLLD003, GLLD012, EQLF002, FELF004, GLLD008, FELF003, JVJF002, DCJB001, JVJF005, YYYY015, YYYY020, YYYY001, YYYY002 | Intensive care unit   |
| <b>ICD10 – associated diagnosis</b>  | <b>Diagnosis</b>  |
| E66*   | Obesity   |
| L97, L984  | Chronic ulcer of lower limb   |
| I21, I22, I23, I24   | Myocardial infarction   |
| I60, I61, I62, I63, I64  | Stoke   |
| G45  | Transient ischemic attack   |
| I7001, I7021, I7081 and R02  | Arteriopathy with gangrene  |
| M86, A46, L02, L03, L04, L08, L303, L304   | Osteomyelitis and skin infection  |

4  
 5  
 6  
 7

1 **Supplementary Table 3: Categorization of rehospitalizations as complications using**  
 2 **groupage of diagnosis, procedures, grouping of patients by a medical expert**

| <b>Categories of complications</b>                     | <b>Diagnostic (ICD10 codes) / Medical procedures CCAM / GHM (patient grouping algorithm based on ICD10 and CCAM codes)</b> |
|--|--|
| <b>Endovascular procedure-related complication</b>     |  |
| hemorrhage   | DP: D62, K66.1, T81.0, R57.1, N50.1, Z51.3 or<br>GHM root: 21C05 or 05C18  |
| aneurysm   | DP: I72.*, I77.2 or<br>CCAM: EESF***, EDPA001, EDPA005   |
| gangrene, ulcer (without amputation)                   | DP: I70.21, I70.81, L97, R02, S81.8, S91.3<br>GHM root not in 05C12 or 05C13   |
| amputation   | GHM root: 05C12 or 05C13   |
| embolism and thrombosis                                | DP: I74.3, I74.4, I74.5  |
| lower limb contusion                                   | DP: S70.0, S70.1, S80.0, S80.1   |
| lower limb pain  | DP: M79.6, M79.65, M79.66<br>CCAM: AJFA001-2-3, AJFC001-2  |
| sepsis   | DP: A41.0, A41.5   |
| acquired arteriovenous fistula                         | DP: I70.0  |
| <b>Heart diseases</b>                                  |  |
| heart failure and circulatory shock                    | DP: I50, R57.0 or GHM root: 05M09  |
| other coronary artery diseases                         | DP: I24, I25 or GHM root: 05M16  |
| angor  | DP: I20 or GHM root: 05M06   |
| arrhythmia   | DP: I44, I45, I47, I48 or<br>GHM root: 05M08   |
| myocardial infarction                                  | DP: I21 or<br>GHM root: 05K05, 05M04   |
| chest pain   | DP: R07 or GHM root: 05M13   |
| cardiac arrest with death                              | GHM: 05M22E  |
| <b>Stroke</b>  |  |
| Strokes constituted                                    | DP: I60, I61, I63<br>GHM root: 01M30, 01M31, 01M36   |
| transient ischemic attack                              | GHM root: 01M15, 01M16   |
| <b>Other cardiovascular diseases</b>                   |  |
| peripheral vascular disorder without revascularization | GHM root: 05M12  |
| syncopes and lipothymias                               | GHM root: 05M05  |
| phlebitis  | DP: I80 or GHM root: 05M07   |
| high blood pressure                                    | GHM root: 05M15  |
| pulmonary embolism                                     | GHM root: 04M10  |
| <b>Other reasons</b>                                   |  |
| other complications related to the procedure           | DP: I97.8, T81.7, T82.3, T82.7, Z09.0, Z48.0, Z48.8 or<br>CCAM: EDCA004, EEGA001-2   |

DP: principal diagnosis ; CCAM French nomenclature of medical procedures ; GHM: homogeneous group of patients

3



1 **Supplementary Table 4: Characteristics of patients and hospitals at the index**  
 2 **endovascular revascularization after propensity score weighting**


|   | <b>Outpatients<br/>(n = 2.819)</b> | <b>Inpatients<br/>(n = 23.896)</b> | <b>Standardized<br/>differences <sup>a</sup></b> |
|---|------------------------------------|------------------------------------|--|
| Age in years (mean ± SD)  | 67.37 (10.73)                      | 67.74 (11.52)                      | 0.033  |
| Women – n (%)   | 738.3 (26.1)                       | 6324.3 (26.5)                      | 0.009  |
| Comorbidities – n (%)   |                                    |                                    |  |
| Myocardial infarction   | 142.2 (5.0)                        | 1140.2 (4.8)                       | 0.012  |
| Congestive heart failure  | 288.3 (10.2)                       | 1843.9 (7.7)                       | 0.086  |
| Stroke (hemiplegia excluded)                                    | 159.3 (5.6)                        | 1228.3 (5.1)                       | 0.021  |
| Dementia  | 26.3 (0.9)                         | 167.2 (0.7)                        | 0.026  |
| Chronic obstructive pulmonary disease                           | 299.3 (10.6)                       | 2083.1 (8.7)                       | 0.063  |
| Connective tissue disease                                       | 11.3 (0.4)                         | 126.2 (0.5)                        | 0.019  |
| Peptic ulcer  | 6.3 (0.2)                          | 90.2 (0.4)                         | 0.028  |
| Mild liver failure  | 1992.3 (70.4)                      | 16600.9 (69.5)                     | 0.019  |
| Diabetes without complications                                  | 32.0 (1.1)                         | 235.1 (1.0)                        | 0.014  |
| Diabetes with organ damage                                      | 330.2 (11.7)                       | 2489.9 (10.4)                      | 0.040  |
| Hemiplegia  | 29.2 (1.0)                         | 183.7 (0.8)                        | 0.028  |
| Moderate or severe kidney failure                               | 150.1 (5.3)                        | 1044.3 (4.4)                       | 0.043  |
| Cancer  | 78.7 (2.8)                         | 646.8 (2.7)                        | 0.004  |
| Moderate or severe liver failure                                | 10.1 (0.4)                         | 67.2 (0.3)                         | 0.013  |
| Metastatic solid tumor  | 13.0 (0.5)                         | 94.2 (0.4)                         | 0.010  |
| HIV with or without AIDS  | 8.5 (0.3)                          | 55.7 (0.2)                         | 0.013  |
| Year of intervention - n (%)                                    |                                    |                                    | 0.040  |
| 2013 <sup>b</sup>   | 658.2 (23.2)                       | 5600.1 (23.4)                      |  |
| 2014  | 806.2 (28.5)                       | 7187.9 (30.1)                      |  |
| 2015  | 895.0 (31.6)                       | 7241.3 (30.3)                      |  |
| 2016 <sup>c</sup>   | 472.2 (16.7)                       | 3865.9 (16.2)                      |  |
| Number of interventions by hospital activity level <sup>d</sup> |                                    |                                    | 0.082  |
| ≤ 100   | 189.7 (6.7)                        | 1716.6 (7.2)                       |  |
| 100-200   | 692.6 (24.5)                       | 5241.4 (21.9)                      |  |
| 200-300   | 359.0 (12.7)                       | 3422.1 (14.3)                      |  |
| 300-400   | 446.6 (15.8)                       | 3982.5 (16.7)                      |  |
| 400-500   | 219.5 (7.8)                        | 1643.5 (6.9)                       |  |
| > 500   | 924.3 (32.6)                       | 7889.0 (33.0)                      |  |

3  
4

1

2 **Supplementary Figure 1: Number of deaths and postsurgical acute care hospitalizations**  
3 **for complications after LEAD endovascular stenting, whatever the clinical setting (n=1,**  
4 **267)**

5



6  
7